FASCINATION ABOUT 2'

Contraindicated (1)bortezomib will enhance the amount or outcome of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Potent or reasonable CYP2C19 inhibitors may possibly enhance mavacamten systemic exposure, causing coronary heart failure as a consequence of systolic dysfunction.Notify your medical professional In case